Equity Analysis /
United States of America

US : NGM Biopharmaceuticals, Inc. - NGM | 3Q21 Update: Active Oncology Programs with GA Data Party Still on Horizon (2H22)

    Contributors
    Timur Ivannikov
    Ryan Deschner
    CGS-CIMB
    4 November 2021
    Published by